The Life Sciences and M&A teams advised ImCheck Therapeutics, a clinical-stage biotechnology company pioneering next-generation immuno-oncology therapies, in its definitive agreement to be acquired by Ipsen (Euronext: IPN; ADR: IPSEY). Under the terms of the agreement, ImCheck’s shareholders will receive €350 million at closing, subject to customary cash/debt adjustments, with the potential for additional milestone-based payments bringing the total transaction valuation to up to €1 billion. The transaction is expected to close by the end of the first quarter of 2026, subject to customary regulatory approvals.
ImCheck Therapeutics is developing a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel superfamily of immunomodulators. By unlocking the power of γ9δ2 T cells, ImCheck’s innovative approach has the potential to transform treatments across oncology, autoimmune, and infectious diseases.
The Goodwin team was led by Graham Defries and Kenny Walker-Durrant, with assistance from Mike Grainger and Rachel Conder.
Centerview Partners were the bankers for the transaction.
For more information on the deal, please read the press release.